Viking Therapeutics Stock Stages Impressive Recovery

Viking Therapeutics shares registered substantial double-digit gains late last week, propelled by favorable sector developments and sustained bullish sentiment among Wall Street analysts.

The biopharmaceutical company’s stock surged 12.78% on Thursday, maintaining strong momentum with elevated trading volumes through Friday’s session. Although shares closed slightly lower at $25.40 (down 2.46%), this minor pullback followed significant prior-day gains and substantial early trading advances.

Industry Consolidation Fuels Optimism

Recent merger and acquisition activity within the biotechnology sector served as the primary catalyst for renewed investor interest. Roche’s acquisition announcement of MASH-focused 89bio generated positive reverberations throughout the industry. Viking Therapeutics stands to benefit from this increased attention given its own MASH candidate, VK2809.

This sector-wide enthusiasm coincides with a reassessment of Viking’s recent developments. In mid-August, the company’s stock had declined over 40% following Phase 2 topline results for its oral obesity treatment VK2735. While the medication demonstrated significant weight loss efficacy, elevated discontinuation rates in the highest dosage cohort concerned some investors. Subsequent analysis suggests the market reaction may have been overstated, as most adverse events were characterized as mild to moderate.

Should investors sell immediately? Or is it worth buying Viking Therapeutics?

Rebounding From Oversold Conditions

The substantial selloff on August 19 created a notably lower valuation entry point. Viking’s flagship candidate VK2735 represents a dual GLP-1/GIP agonist—the same therapeutic class that has driven remarkable commercial success for industry leaders Eli Lilly and Novo Nordisk in the expanding obesity market.

Despite concerns regarding the oral formulation, Viking is concurrently developing an injectable version of VK2735 already advancing through Phase 3 trials. The stock’s dramatic recovery indicates shifting investor sentiment, with many now viewing the previous selloff as a potential buying opportunity.

• Substantial liquidity: $808 million cash position as of Q2 2025
• Dual market opportunity: Positioned in both obesity and MASH therapeutics
• Advanced pipeline: Phase 3 trials supported by strong financial resources

Upcoming Catalysts

Viking Therapeutics approaches several critical milestones. The market anticipates complete Phase 2 VENTURE study topline results for oral VK2735 during the latter half of 2025. More significantly, progress in the Phase 3 VANQUISH program for the injectable formulation will likely determine the company’s future trajectory.

The next quarterly update is expected by late October. Investors will closely monitor developments regarding research expenditures and trial timelines. Analyst consensus remains strongly positive, reflecting continued confidence in the long-term potential of Viking’s product pipeline.